← Back to headlines
Context Therapeutics Stock Rises on FDA Fast Track Status
Context Therapeutics saw its stock rise after its lead asset was granted fast track status by the FDA.
2 Apr, 15:27 — 2 Apr, 15:27
Sources
Showing 1 of 1 sources
Context Therapeutics saw its stock rise after its lead asset was granted fast track status by the FDA.
